NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017
2017; National Comprehensive Cancer; Volume: 15; Issue: 5 Linguagem: Inglês
10.6004/jnccn.2017.0059
ISSN1540-1413
AutoresAl B. Benson, Michael I. D’Angelica, Daniel E. Abbott, Thomas A. Abrams, Steven R. Alberts, Daniel A. Anaya, Chandrakanth Are, Daniel B. Brown, Daniel T. Chang, Anne M. Covey, William G. Hawkins, Renuka Iyer, Rojymon Jacob, Andrea Karachristos, Robin Kate Kelley, Robin D. Kim, Manisha Palta, James O. Park, Vaibhav Sahai, Tracey E. Schefter, Carl Schmidt, Jason K. Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, Guo Tian, Jean‐Nicolas Vauthey, Alan P. Venook, Andrew X. Zhu, K Hoffmann, Susan Darlow,
Tópico(s)Pancreatic and Hepatic Oncology Research
ResumoThe NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.
Referência(s)